At the third annual Interactive @entity5464 Conference, held in Budapest from 30 April to 1 May 2011, the latest developments in the management of @entity1 with high-risk localised and @entity263 were discussed. @entity263 is the most common @entity5 in Western @entity1 and, for @entity1442 , no curative agents are available. For @entity1 with high-risk localised disease there is debate about the best treatment approaches, with both radical prostatectomy and radiation therapy shown to improve outcomes. These approaches have started to be augmented as new techniques and therapies are developed. For instance, radiation therapy combined with @entity342 deprivation therapy has been shown to be more efficacious than radiation therapy alone, and there may also be a role for adjuvant/neoadjuvant chemotherapy. Ultimately a multidisciplinary approach will most probably result in the best outcomes for @entity1 . The use of @entity342 deprivation therapy in @entity1 with @entity263 needs to be monitored carefully, given that it results in adverse alterations in several metabolic parameters and an increased risk of further coronary events in @entity1 with @entity65 in some studies. Until recently there were limited options for the management of @entity1 with @entity263 , but new agents for use in the post-docetaxel setting have recently been approved. These are @entity15513 and @entity15512 , which have both shown a significant survival benefit in @entity1 who have progressed on @entity1205 . Additional agents, for these @entity1 and for @entity1 at other stages of disease, are in the later stages of development. The development of new agents has been aided by a greater understanding of the molecular mechanisms of resistance to current therapies and the recognition of new pathophysiological pathways. As the number of available therapeutic options increases, it will become increasingly important to tailor treatments to the individual @entity1 . This may require the development of novel biomarkers or the use of existing or new predictive tools based on prognostic factors. To ensure optimal @entity1 care, early and continuous involvement of the multidisciplinary team will be required.

Advances in the management of high-risk localised and XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men'] @entity263 :: ('MESH:D011471', 'Disease') :: ['metastatic prostate cancer', 'prostate cancer', 'Prostate cancer', 'advanced prostate cancer'] @entity15512 :: ('MESH:C089742', 'Chemical') :: ['abiraterone acetate'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity5464 :: ('MESH:D014565', 'Disease') :: ['Genitourinary Cancer'] @entity1442 :: ('MESH:D020178', 'Disease') :: ['advanced disease'] @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen'] @entity15513 :: ('MESH:C552428', 'Chemical') :: ['cabazitaxel'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease']
@entity263 :: (MESH:D011471,Disease) :: ['metastatic prostate cancer']
